TD Asset Management Inc Lowers Holdings in IDEXX Laboratories, Inc. $IDXX

TD Asset Management Inc trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 11.9% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 267,850 shares of the company’s stock after selling 36,340 shares during the period. TD Asset Management Inc owned approximately 0.34% of IDEXX Laboratories worth $181,209,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC grew its position in IDEXX Laboratories by 2.5% in the third quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock worth $397,000 after acquiring an additional 15 shares during the period. Harbour Investments Inc. lifted its stake in IDEXX Laboratories by 13.3% during the fourth quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock worth $92,000 after purchasing an additional 16 shares in the last quarter. CWA Asset Management Group LLC lifted its stake in IDEXX Laboratories by 3.5% during the fourth quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock worth $344,000 after purchasing an additional 17 shares in the last quarter. Stratos Wealth Partners LTD. lifted its stake in IDEXX Laboratories by 1.7% during the third quarter. Stratos Wealth Partners LTD. now owns 1,069 shares of the company’s stock worth $683,000 after purchasing an additional 18 shares in the last quarter. Finally, Cary Street Partners Investment Advisory LLC lifted its stake in IDEXX Laboratories by 11.5% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 174 shares of the company’s stock worth $111,000 after purchasing an additional 18 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IDXX has been the topic of a number of research reports. UBS Group decreased their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Piper Sandler decreased their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Stifel Nicolaus decreased their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Finally, Citigroup initiated coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Stock Up 0.7%

Shares of NASDAQ IDXX opened at $564.74 on Friday. The stock has a market cap of $44.55 billion, a P/E ratio of 41.59, a PEG ratio of 3.07 and a beta of 1.55. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98. The business’s fifty day simple moving average is $563.32 and its 200-day simple moving average is $632.63.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period last year, the firm earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.